Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Ernexa Therapeutics announced preclinical data demonstrating that their lead cell therapy candidate ERNA-101, combined with PD-1 blockade, achieved complete tumor clearance and 100% survival in ovarian cancer mouse models. This novel therapy remodels the tumor microenvironment from immunosuppressive to immune-activated, enhancing the efficacy of ch…